Technical Analysis for NGM - NGM Biopharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 15.45 -3.44% -0.55
NGM closed down 3.44 percent on Thursday, April 18, 2019, on 45 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical NGM trend table...

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Hot IPO Pullback Bullish Swing Setup -3.44%
NR7 Range Contraction -3.44%
Inside Day Range Contraction -3.44%
Shooting Star Candlestick Bearish -3.44%
New 52 Week High Strength -3.44%
Hot IPO Pullback Bullish Swing Setup -3.80%
NR7 Range Contraction -3.80%
Inside Day Range Contraction -3.80%

Older signals for NGM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity. Its products under development also comprise NGM120, an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in preclinical studies to decrease levels of a protein implicated in the dry form of age-related macular degeneration. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp., MedImmune Limited, and JDRF International. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Diabetes Pharmacy Monoclonal Antibodies Obesity Age Related Macular Degeneration Treatment Of Obesity Ophthalmic Diseases
Is NGM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 18.75
52 Week Low 14.5
Average Volume 221,705
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 15.888
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0
MACD Signal Line 0.0
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.43
Resistance 3 (R3) 17.55 17.01 17.10
Resistance 2 (R2) 17.01 16.51 16.95 16.99
Resistance 1 (R1) 16.23 16.19 15.96 16.11 16.88
Pivot Point 15.69 15.69 15.56 15.63 15.69
Support 1 (S1) 14.91 15.19 14.64 14.79 14.02
Support 2 (S2) 14.37 14.87 14.31 13.91
Support 3 (S3) 13.59 14.37 13.80
Support 4 (S4) 13.47